New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
07:03 EDTITMNInterMune announces resubmission of NDA for Perfernidone
InterMune announced that it has resubmitted its pirfenidone New Drug Application to the FDA in response to a Complete Response Letter received in May 2010. Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis. Under the Prescription Drug User Fee Act, the FDA has 74 days after receipt of an NDA to evaluate the submission in order to determine if it is sufficiently complete. If in this 74-day period the FDA determines that the submission is complete, the review clock will be deemed to have started as of the date that the resubmission was initially received by the FDA. As the resubmission of an efficacy supplement, the submission of the ASCEND data represents a Class 2 resubmission that has a target FDA review of six months under PDUFA V.
News For ITMN From The Last 14 Days
Check below for free stories on ITMN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 14, 2014
10:05 EDTITMNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Adidas (ADDYY) downgraded to Neutral from Buy at Goldman... Fabrinet (FN) downgraded at B. Riley... Freeport McMoRan (FCX) downgraded at Stifel... Infosys (INFY) downgraded to Hold from Buy at Jefferies... InterMune (ITMN) downgraded to Neutral from Buy at Goldman... Jones Energy (JONE) downgraded to Neutral from Overweight at JPMorgan... LVMH Moet Hennessy (LVMUY) downgraded to Neutral from Buy at Goldman... Madison Square Garden (MSG) downgraded to Hold from Buy at Topeka... Qualys (QLYS) downgraded to Sector Perform from Outperform at RBC Capital... SeaWorld (SEAS) downgraded to Market Perform from Outperform at Wells Fargo... Theravance Biopharma (TBPH) downgraded to Underperform from Neutral at RW Baird... URS Corporation (URS) downgraded to Neutral from Buy at Sterne Agee... ViaSat (VSAT) downgraded to Perform from Outperform at Oppenheimer... Wynn Resorts (WYNN) downgraded to Hold from Buy at Gabelli.
09:11 EDTITMNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Kohl's (KSS), up 2.5%... Plug Power (PLUG), up 10%... Perrigo (PRGO), up 4.5%. HIGHER: Aruba Networks (ARUN), up 3% after shares upgraded at Stifel... KaloBios (KBIO), up 7.9% after publication shows EphA3 as target for anticancer therapy... Supernus (SUPN), up 4.4% after receiving FDA fast track designation for SPN-810. DOWN AFTER EARNINGS: Noodles & Company (NDLS), down 22%... Vipshop (VIPS), down 5.8%. LOWER: ExOne (XONE), down 10.7%, Voxeljet (VJET), down 6.6%, after earnings reports. Peers in the 3D space are lower as well, with Stratasys (SSYS) down 1% and 3D Systems (DDD) down 0.2%... Enphase Energy (ENPH), down 2.6% after filing to sell common stock for holders... InterMune (ITMN), down 3% after downgraded at Goldman following yesterday's advance on Bloomberg report that the company received takeover bids from Sanofi (SNY), Roche (RHHBY).
05:28 EDTITMNInterMune downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded InterMune (ITMN) to Neutral citing valuation after the stock rallied on a Bloomberg report of takeover interest. Goldman continues to expect InterMune's Esbriet for orphan lung disease will receive FDA approval on or before the November 23 action date. The firm has a $49 price target for shares, which closed yesterday up 14% to $52.06.
August 13, 2014
16:19 EDTITMNOn The Fly: Closing Wrap
Subscribe for More Information
13:29 EDTITMNInterMune options active after Bloomberg report of takeover bids
Subscribe for More Information
13:13 EDTITMNInterMune exploring sale after bids from Sanofi, Roche, Glaxo, Bloomberg says
InterMune (ITMN) is working with its financial advisers Goldman Sachs (GS) and Centerview Partners to evaluate takeover bids it has received from Sanofi (SNY), Roche (RHHBY), GlaxoSmithKline (GSK) and Actelion (ALIOF), said Bloomberg, citing people with knowledge of the matter. The report noted that one of the sources said Sanofi has so far shown the most interest in a deal for InterMune, whose shares are up more than 13% to $51.56 following the first headlines from the report. Reference Link
13:02 EDTITMNInterMune jumps 20% to $54.57 after Bloomberg report of takeover bids
Subscribe for More Information
13:01 EDTITMNInterMune working with banks on sale after bids, Bloomberg reports
Subscribe for More Information
13:00 EDTITMNInterMune received takeover bids from Sanofi, Roche, Bloomberg says
August 11, 2014
15:23 EDTITMNInterMune rumored to be working with adviser to explore options, Betaville says
Subscribe for More Information
15:22 EDTITMNInterMune August volatility increases on wide price movement
Subscribe for More Information
August 6, 2014
16:11 EDTITMNInterMune sees FY14 Esbriet revenue at higher end of $130M-$140M
Subscribe for More Information
16:10 EDTITMNInterMune reports Q2 EPS (72c), consensus (56c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use